P156

Q3 Medicine
D. Kokova , N. Dementeva , N. Cherdyntseva , A. Gratchev , Julia Kzhyshkowska
{"title":"P156","authors":"D. Kokova ,&nbsp;N. Dementeva ,&nbsp;N. Cherdyntseva ,&nbsp;A. Gratchev ,&nbsp;Julia Kzhyshkowska","doi":"10.1016/j.ejcsup.2015.08.048","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Identification of DNA-based biomarkers of cancer cells is highly promising and rapidly developing direction that can advance early detection and therapy of malignancies. DNA adducts are felicitous markers of cancer, because their chemical structure is significantly different from that of mutated or methylated DNA, that allows to determine them with high precision using mass spectrometry. The aim of this work is to develop the methodology of sample preparation and its mass spectrometric analysis. Samples were prepared from the blood plasma and from the tumor tissue from lung cancer patients and from blood of healthy individuals.</p></div><div><h3>Materials and methods</h3><p>DNA was isolated from the blood plasma and tissue by using column method (BioSilica, Russia) The final yield from 1<!--> <!-->ml of blood was 100<!--> <!-->ng. DNA samples were subjected to acid hydrolysis (1<!--> <!-->M HCl) at 70<!--> <!-->°C. After 3<!--> <!-->h, the hydrolysis was stopped by cooling on ice for 5<!--> <!-->min and later on adding an equivalent amount of an alkali and a phosphate buffer solution (pH 7). To assess the extent of hydrolysis of the samples they were analysed by electrophoresis on a 1.2% agarose gel in Tris-acetate buffer. The samples were extracted at cartridge HF Bond Elut-C18 100<!--> <!-->mg, 1<!--> <!-->ml (Agilent Technologies, USA) and eluted in several fractions with a gradual increase of methanol in the eluent. Stream of nitrogen was applied to dry the extract. The samples were subjected to mass spectrometric analysis after pre-separation by UHLC Ultimate 3000 RS (Dionex, USA) in a column Dionex Acclaim RSLC 120 C18 (2.1<!--> <!-->×<!--> <!-->50<!--> <!-->mm 120<!--> <!-->A, 0.2<!--> <!-->μm) flow rate of 0.5<!--> <!-->ml/min using as eluents 0.1% solution of formic acid in water (A) and 0.1% solution of formic acid in atsetontrile (B). Elution was carried out in gradient mode: (%B): 0–3min (5%), 3–28min (5–95%), 28–30<!--> <!-->min (95%), 30–31<!--> <!-->min (95–5%), 31–35<!--> <!-->min (5%). Mass spectrometry was carried out on ESI-qTOF ultrahigh resolution Maxis 4G (Bruker, Germany) in the positive ion detection mode range 50–1000<!--> <!-->m/z, 2<!--> <!-->Hz with the following settings electrospray ion source: CV 3800<!--> <!-->V, Nebulizer gas 1<!--> <!-->bar, Dry Gas 8 l/min, Dry Temp: 200<!--> <!-->°C.</p></div><div><h3>Results</h3><p>It was found that the DNA which was cleaved with acid hydrolysis in the result contained single DNA bases. The samples were stable at 4<!--> <!-->°C for at least 7<!--> <!-->days. The optimal eluent for solid phase extraction of DNA is 80% solution of methanol in water. The number of DNA adducts was evaluated by the integrated value of the mass spectrometric response detector. It was shown that most amount of adducts 4-hydroxy-1-(3-pyridyl)-1- butanone and N3-(2-carbamoyl-2-hydroxyethyl)adenine was found in DNA samples derived from tumor tissue. The adduct N7-(2-carbamoyl-2-hydroxyethyl)guanine was found in tumor tissue samples and DNA derived from plasma, as well as in all samples of healthy tissue.</p></div><div><h3>Conclusion</h3><p>The established protocol of DNA sample preparation followed by analysis using a mass spectrometer high resolution allows to detect the content of the DNA adducts in small DNA probes (100<!--> <!-->ng). We found, that acid hydrolysis is cheaper and more practical in comparison to enzymatic digestion in order to generated samples containing single DNA bases without damaging the structure of adducts.</p><p><em>This research was supported by Federal Targeted Programme for Research and Development in Priority Areas of Development of the Russian Scientific and Technological Complex for 2014–2020, “Development of molecular signatures for early detection of lung cancer” (No. 14.575.21.0064 from 05.08.2014, RFMEFI57514X0064) and supported by Tomsk State University, Competitiveness Improvement Program”.</em> Work was conducted with the application of the Tomsk regional common use center technical equipment acquired thanks to a grant of the Russian Ministry of the Agreement No.14.594.21.0001 (RFMEFI59414X0001).</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"13 1","pages":"Pages 27-28"},"PeriodicalIF":0.0000,"publicationDate":"2015-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejcsup.2015.08.048","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejc Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S135963491500049X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Background

Identification of DNA-based biomarkers of cancer cells is highly promising and rapidly developing direction that can advance early detection and therapy of malignancies. DNA adducts are felicitous markers of cancer, because their chemical structure is significantly different from that of mutated or methylated DNA, that allows to determine them with high precision using mass spectrometry. The aim of this work is to develop the methodology of sample preparation and its mass spectrometric analysis. Samples were prepared from the blood plasma and from the tumor tissue from lung cancer patients and from blood of healthy individuals.

Materials and methods

DNA was isolated from the blood plasma and tissue by using column method (BioSilica, Russia) The final yield from 1 ml of blood was 100 ng. DNA samples were subjected to acid hydrolysis (1 M HCl) at 70 °C. After 3 h, the hydrolysis was stopped by cooling on ice for 5 min and later on adding an equivalent amount of an alkali and a phosphate buffer solution (pH 7). To assess the extent of hydrolysis of the samples they were analysed by electrophoresis on a 1.2% agarose gel in Tris-acetate buffer. The samples were extracted at cartridge HF Bond Elut-C18 100 mg, 1 ml (Agilent Technologies, USA) and eluted in several fractions with a gradual increase of methanol in the eluent. Stream of nitrogen was applied to dry the extract. The samples were subjected to mass spectrometric analysis after pre-separation by UHLC Ultimate 3000 RS (Dionex, USA) in a column Dionex Acclaim RSLC 120 C18 (2.1 × 50 mm 120 A, 0.2 μm) flow rate of 0.5 ml/min using as eluents 0.1% solution of formic acid in water (A) and 0.1% solution of formic acid in atsetontrile (B). Elution was carried out in gradient mode: (%B): 0–3min (5%), 3–28min (5–95%), 28–30 min (95%), 30–31 min (95–5%), 31–35 min (5%). Mass spectrometry was carried out on ESI-qTOF ultrahigh resolution Maxis 4G (Bruker, Germany) in the positive ion detection mode range 50–1000 m/z, 2 Hz with the following settings electrospray ion source: CV 3800 V, Nebulizer gas 1 bar, Dry Gas 8 l/min, Dry Temp: 200 °C.

Results

It was found that the DNA which was cleaved with acid hydrolysis in the result contained single DNA bases. The samples were stable at 4 °C for at least 7 days. The optimal eluent for solid phase extraction of DNA is 80% solution of methanol in water. The number of DNA adducts was evaluated by the integrated value of the mass spectrometric response detector. It was shown that most amount of adducts 4-hydroxy-1-(3-pyridyl)-1- butanone and N3-(2-carbamoyl-2-hydroxyethyl)adenine was found in DNA samples derived from tumor tissue. The adduct N7-(2-carbamoyl-2-hydroxyethyl)guanine was found in tumor tissue samples and DNA derived from plasma, as well as in all samples of healthy tissue.

Conclusion

The established protocol of DNA sample preparation followed by analysis using a mass spectrometer high resolution allows to detect the content of the DNA adducts in small DNA probes (100 ng). We found, that acid hydrolysis is cheaper and more practical in comparison to enzymatic digestion in order to generated samples containing single DNA bases without damaging the structure of adducts.

This research was supported by Federal Targeted Programme for Research and Development in Priority Areas of Development of the Russian Scientific and Technological Complex for 2014–2020, “Development of molecular signatures for early detection of lung cancer” (No. 14.575.21.0064 from 05.08.2014, RFMEFI57514X0064) and supported by Tomsk State University, Competitiveness Improvement Program”. Work was conducted with the application of the Tomsk regional common use center technical equipment acquired thanks to a grant of the Russian Ministry of the Agreement No.14.594.21.0001 (RFMEFI59414X0001).

P156
基于dna的肿瘤细胞生物标志物的鉴定是一个非常有前途和快速发展的方向,可以促进恶性肿瘤的早期发现和治疗。DNA加合物是癌症的有利标记物,因为它们的化学结构与突变或甲基化的DNA明显不同,这使得使用质谱法可以高精度地确定它们。本工作的目的是发展样品制备及其质谱分析的方法。从肺癌患者的血浆和肿瘤组织以及健康人的血液中制备样品。材料和方法采用柱法(BioSilica, Russia)从血浆和组织中分离dna, 1 ml血液的最终产率为100 ng。DNA样品在70°C下进行酸水解(1 M HCl)。3小时后,通过在冰上冷却5分钟,然后加入等量的碱和磷酸盐缓冲溶液(pH 7)来停止水解。为了评估样品的水解程度,我们在Tris-acetate缓冲液中使用1.2%琼脂糖凝胶进行电泳分析。样品在HF Bond Elut-C18滤盒中提取100 mg, 1 ml (Agilent Technologies, USA),分几段洗脱,洗脱液中甲醇的含量逐渐增加。用氮气流干燥提取物。样品采用美国Dionex公司的uhplc Ultimate 3000 RS进行预分离,色谱柱为Dionex公司的Acclaim公司RSLC 120 C18 (2.1 × 50 mm 120 a, 0.2 μm),流速为0.5 ml/min,洗脱液为0.1%甲酸水溶液(a)和0.1%甲酸atsetontrile溶液(B)。洗脱液为梯度模式:(%B): 0-3min(5%)、3-28min(5-95%)、28-30 min(95%)、30-31 min(95-5%)、31-35 min(5%)。质谱分析在ESI-qTOF超高分辨率Maxis 4G (Bruker, Germany)上进行,正离子检测模式范围为50-1000 m/z, 2hz,设置电喷雾离子源:CV 3800 V, Nebulizer气体1 bar, Dry gas 8 l/min, Dry temperature: 200°C。结果发现酸水解裂解的DNA含有单个碱基。样品在4℃下稳定保存至少7天。固相萃取DNA的最佳洗脱液为80%甲醇水溶液。通过质谱响应检测器的积分值评估DNA加合物的数量。结果表明,肿瘤组织DNA样品中含有最多的加合物4-羟基-1-(3-吡啶基)-1-丁酮和N3-(2-氨基甲酰-2-羟乙基)腺嘌呤。在肿瘤组织样本和血浆DNA以及所有健康组织样本中发现了N7-(2-氨基甲酰-2-羟乙基)鸟嘌呤加合物。结论所建立的DNA样品制备和高分辨率质谱仪分析方案可以在100 ng的小DNA探针中检测DNA加合物的含量。我们发现,为了生成含有单个DNA碱基的样品而不破坏加合物的结构,与酶消化相比,酸水解更便宜,更实用。这项研究得到了俄罗斯科学技术综合体2014-2020年优先发展领域联邦研究与开发目标计划“早期检测肺癌分子特征的开发”(2014年8月5日№14.575.21.0064,RFMEFI57514X0064)的支持,并得到了托木斯克国立大学“竞争力提高计划”的支持。工作是利用托木斯克地区通用中心的技术设备进行的,这些技术设备是由俄罗斯政府根据第14.594.21.0001号协议(RFMEFI59414X0001)授予的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Ejc Supplements
Ejc Supplements 医学-肿瘤学
自引率
0.00%
发文量
0
审稿时长
3.7 months
期刊介绍: EJC Supplements is an open access companion journal to the European Journal of Cancer. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in EJC Supplements are made openly available through the journal''s websites. EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention. Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief. EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信